Social Media Ideas for Eli Lilly

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Calif. Judge Hands Eli Lilly Mixed Bag In Compound Drug Suit

Eli Lilly failed to plausibly allege that a physician group and pharmacy conspired to falsely advertise compounded versions of its diabetes and weight loss drugs, but can continue...

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

Eli Lilly’s $100B incretin opportunity: Is more upside coming?

Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next 

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli Lilly’s pipeline in 2026: how the incretin...

Pharma AI Citation Share: Eli Lilly Leads Rx

Discover why Eli Lilly and Novo Nordisk lead pharma AI citation share in 2026, driven by GLP-1 drugs. Learn how AI engines prioritize content over ad spend.

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

The drug giant added to its immunotherapy portfolio.

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a...

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.

Hardly for the first time recently, the company is making a pricey acquisition.

Lilly wins EU backing for Foundayo weight-loss pill

This New Zepbound Study Could Be Great News for Eli Lilly Investors

The high-flying healthcare leader looks unstoppable right now.

Eli Lilly study aims to bolster case for long-term Zepbound benefits

As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare o...

Eli Lilly: Quiet Momentum Builds Into Q3 Earnings, But Watch The Chart Too

<![CDATA[CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report ]]>

Stock Split Watch: Is Eli Lilly Next?

The stock has soared 25% in six months.

Eli Lilly: Impressive Growth, Questionable Valuation

Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare sp...